B-One Ortho, Corp. appears in FDA records at 3 Wing Drive, Suite 259, Cedar Knolls, New Jersey, the address used on its 510(k) correspondence. That filing address is a regulatory contact point, not a verified headquarters. The company's documented identity is tied to the MOBIO Total Knee System, a cemented patellofemorotibial polymer/metal/polymer semi-constrained knee prosthesis. FDA records linked by MedtechLedger show one linked 510(k) record for this applicant, K262341, decided September 8, 2026. Earlier FDA clearance letters for the same device family name Allison Gecik in regulatory roles and describe the MOBIO system under the same regulation number and product code. [1][7][8]
The 2026 revision filing
K262341 covers the b-ONE® Mobio™ Total Knee System Revision Cemented Tibial Augments, Stem Extensions and Press-Fit Stem Extensions. FDA received the submission July 10, 2026, and decided it September 8, 2026 as substantially equivalent under a Traditional clearance with a Summary. The advisory committee and review committee are both recorded as Orthopedic. The FDA decision letter states the purpose of the submission was to expand the current size range for the Tibial Stem Extensions to include five additional sizes, and describes the Press-Fit Stem Extensions as optional components that may be used to provide additional fixation of the knee prosthesis construct. [1][9]
The decision letter also restates the MOBIO Total Knee System intended use, which includes total knee arthroplasty and revision of a previous unsuccessful knee replacement or other procedure. The record lists the device as a Class II prosthesis under regulation 888.3560 with product code JWH. [1][9]
Earlier clearances for the same system
FDA clearance letters from 2021 and 2022 address the MOBIO Total Knee System under the same trade name, regulation number 21 CFR 888.3560, Class II, and product code JWH. The 2021 letter, K210483, describes system components supplied sterile as single-use devices and compares materials of construction, manufacturing processes and sizes offered against predicate devices. The 2022 letter, K222431, repeats the trade and device name and regulation details and references performance data provided in support of the substantial equivalence determination. [7][8]
These letters document a sequence of MOBIO knee filings rather than a single event. They also identify the same regulatory contact, Allison Gecik, across the 2021, 2022 and 2026 correspondence. [7][8][9]
Published product documentation
The manufacturer's surgical technique document describes the MOBIO™ All-in-ONE Total Knee System as an evolution of prosthetic designs in primary total knee reconstruction, and its table of contents lists introduction and system overview plus indications and contraindications. The document carries a 2026 copyright line for b-ONE ORTHO and the Cedar Knolls address. A separate Summary of Safety and Clinical Performance, document EXT-00665 revision A, covers the b-ONE® MOBIO™ Total Knee System and lists named authors, reviewers and approvers in quality and regulatory roles. [4][5]
The product page published by b-ONE names Richard H. Rothman, M.D., Ph.D. and Mark Kester, Ph.D. as lead designers and describes single radius curvature, ligament tension and quadriceps efficiency as design features. Those characterizations are the publisher's own descriptions of the implant design, not independently verified clinical results. [6]
What the record does and does not establish
The linked collection contains one 510(k) record, and that single record carries a substantially equivalent decision. That count describes the linked filings as of the snapshot date; it is not a measure of total company sales, total portfolio or safety performance. No recall records appear in the linked sample. [1]
The records do not establish ownership, a parent company, a brand hierarchy, customers, commercial availability or headquarters. The applicant name appears as B-One Ortho, Corp. in the 2026 record and as b-ONE ORTHO, Corp. in earlier FDA letters and manufacturer documents; the relationship between those name forms is not explained in the cited records. [1][7][8]


